Global Lisinopril Market – Industry Trends and Forecast to 2031

Global Lisinopril Market, By Disease (Hypertension, Heart Failure, Heart Attack, Strokes, Diabetic Kidney Disease, Others), Dosage (Tablet, Liquid, Others), Dosage Strength (10mg/12.5mg, 20mg/12.5mg, 20mg/25mg, Others), Brand (Zestoretic, Prinivil, Zestril, Others), Population Type (Children, Adults), End-Users (Hospitals, Specialty Clinics, Home Healthcare, Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2031.

Lisinopril Market Analysis and Size   

The increase in the prevalence of hypertension and other cardiovascular diseases is expected to drive the market growth. In addition, an increase in the demand for less expensive drugs to manage medical conditions associated with the cardiovascular system positively affects the market. The rise in healthcare expenditure in developing countries further extends profitable opportunities to the market players.

Data Bridge Market Research analyses that the global lisinopril market which was USD 226.46 million in 2023, would reach up to USD 317.15 million by 2031, and is expected to undergo a CAGR of 4.30% during the forecast period. The “hypertension” in disease segment is expected to dominate the global lisinopril market due to greater usage of lisinopril in controlling the hypertension. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Lisinopril Market Scope and Segmentation

Market Definition

Lisinopril is the anhydrous form of a long-acting Angiotensin-Converting Enzyme (ACE) inhibitor with anti-hypertensive activity. It is a peptide derivative that inhibits ACE and competitively binds to ACE, ultimately blocking the conversion of angiotensin I to angiotensin II. The common side effects of lisinopril are headache, dizziness, persistent cough, low blood pressure, and chest pain among others.

Global Lisinopril Market Dynamics

Drivers

• Rising Prevalence of Hypertension and Cardiovascular Diseases

The escalating global burden of hypertension and cardiovascular diseases is a primary driver for the global lisinopril market. As lifestyles become more sedentary and dietary habits less healthy, the demand for antihypertensive medications, including lisinopril, continues to rise. This trend is particularly pronounced in aging populations where cardiovascular issues are more prevalent, emphasizing the sustained need for effective treatments like lisinopril.

• Generic Versions and Cost-Effectiveness

The availability of generic lisinopril at more affordable prices enhances its market penetration. As healthcare systems globally seek cost-effective solutions, generic versions of lisinopril offer a viable option for patients, healthcare providers, and payers. This increased accessibility contributes significantly to the widespread adoption of lisinopril, particularly in regions where cost considerations play a pivotal role in healthcare decisions.

Opportunities

• Growing Awareness and Early Diagnosis

Increasing public awareness campaigns and healthcare initiatives focused on hypertension and cardiovascular diseases create opportunities for the global lisinopril market. As more individuals become informed about the risks associated with these conditions, there is a potential for earlier diagnosis and intervention. This not only enhances patient outcomes but also expands the market as healthcare professionals prescribe lisinopril as a front-line treatment for hypertension.

• Combination Therapies

The exploration and development of combination therapies involving lisinopril offer a promising avenue for market growth. Combining lisinopril with other cardiovascular medications or complementary therapeutic agents could provide synergistic effects, addressing multiple aspects of cardiovascular health. This approach may improve treatment efficacy, reduce side effects, and enhance patient adherence, creating a valuable niche within the global lisinopril market.

Restraints/Challenges

• Side Effects and Tolerability Issues

Lisinopril, while generally well-tolerated, can be associated with side effects such as cough, dizziness, and changes in kidney function. The occurrence of these side effects may lead to challenges in patient adherence, necessitating close monitoring by healthcare professionals. Addressing individual patient tolerability is crucial to maintaining long-term compliance with lisinopril therapy and optimizing its benefits in managing hypertension and cardiovascular conditions.

• Emergence of Alternative Therapies

The evolving landscape of cardiovascular pharmacotherapy introduces alternative medications and treatment modalities, posing a challenge to the established position of lisinopril. The emergence of newer classes of antihypertensive drugs and innovative cardiovascular therapies may influence prescribing patterns, with clinicians exploring diverse options based on patient-specific factors and treatment goals. Pharmaceutical companies must adapt to these shifts by emphasizing the unique benefits of lisinopril and its role within comprehensive cardiovascular management.

This global lisinopril market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global lisinopril market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Lisinopril Market Scope

The global lisinopril market is segmented on the basis of disease, dosage, dosage strength, brand, population type, end-users, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Disease

• Hypertension
• Heart Failure
• Heart Attack
• Strokes
• Diabetic Kidney Disease
• Others

Dosage

• Tablet
• Liquid
• Others

Dosage Strength

• 10 Mg/12.5 Mg
• 20 Mg/12.5 Mg
• 20 Mg/25 Mg
• Others

Brand

• Zestoretic
• Prinivil
• Zestril
• Others

Population Type

• Children
• Adults

End-Users

• Hospitals
• Specialty Clinics
• Others

Distribution Channel

• Direct Tender
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Global Lisinopril Market Regional Analysis/Insights

The global lisinopril market is analyzed and market size insights and trends are provided by country, disease, dosage, dosage strength, brand, population type, end-users, and distribution channel as referenced above.

The countries covered in the global lisinopril market are U.S., Canada, Mexico, Germany, France, U.K., Belgium, Lithuania, Austria, Ireland, Norway, Poland, Italy, Spain, Russia, Turkey, Netherlands Switzerland, Rest of Europe, Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel and Rest of Middle East and Africa.

North America dominates the global lisinopril market due to the increased prevalence of hypertension and cardiovascular diseases among the population.

Asia-Pacific is expected to grow at the highest growth rate during the forecast period due to increasing geriatric population and the growing healthcare expenditure in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The global lisinopril market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for global lisinopril market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the global lisinopril Market. The data is available for historic period 2016-2021.

Competitive Landscape and Global Lisinopril Market Share Analysis

The global lisinopril market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global lisinopril market.

Some of the major players operating in the global lisinopril market are:

• Lupin Pharmaceuticals, Inc. (India)
• AstraZeneca (U.K.)
• Merck & Co., Inc. (U.S.)
• Sun Pharmaceutical Industries Limited (India)
• Teva Pharmaceutical Industries Limited (Israel)
• Cipla Inc. (India)
• Apotex Inc. (Canada)
• Aurobindo Pharma Ltd. (India)
• Vitaris Inc. (U.S.)
• Hikma Pharmaceutical PLC. (U.K.)
• Pfizer Inc. (U.S.)
• Bausch Health Companies, Inc. (Canada)
• AbbVie Inc. (U.S.)
• Torrent Pharmaceuticals (India)
•  Zydus Cadila (India)
• Amneal Pharmaceutical Inc. (U.S.)